nodes	percent_of_prediction	percent_of_DWPC	metapath
Medrysone—Prednisolone—hematologic cancer	0.17	1	CrCtD
Medrysone—NR3C1—hematologic cancer	0.0997	1	CbGaD
Medrysone—Corticosteroid Hormone Receptor Agonists—Betamethasone—hematologic cancer	0.0811	0.209	CiPCiCtD
Medrysone—Corticosteroid Hormone Receptor Agonists—Dexamethasone—hematologic cancer	0.0811	0.209	CiPCiCtD
Medrysone—Corticosteroid Hormone Receptor Agonists—Triamcinolone—hematologic cancer	0.0784	0.202	CiPCiCtD
Medrysone—Corticosteroid Hormone Receptor Agonists—Prednisolone—hematologic cancer	0.0759	0.195	CiPCiCtD
Medrysone—Corticosteroid Hormone Receptor Agonists—Prednisone—hematologic cancer	0.0717	0.185	CiPCiCtD
Medrysone—SERPINA6—Triamcinolone—hematologic cancer	0.0358	0.269	CbGbCtD
Medrysone—SERPINA6—Prednisolone—hematologic cancer	0.0303	0.228	CbGbCtD
Medrysone—NR3C1—Triamcinolone—hematologic cancer	0.0167	0.126	CbGbCtD
Medrysone—NR3C1—Betamethasone—hematologic cancer	0.0144	0.108	CbGbCtD
Medrysone—NR3C1—Prednisolone—hematologic cancer	0.0142	0.106	CbGbCtD
Medrysone—NR3C1—Prednisone—hematologic cancer	0.0134	0.101	CbGbCtD
Medrysone—NR3C1—Dexamethasone—hematologic cancer	0.00835	0.0627	CbGbCtD
Medrysone—Flurandrenolide—Dexamethasone—hematologic cancer	0.0044	0.0276	CrCrCtD
Medrysone—Flurandrenolide—Betamethasone—hematologic cancer	0.0044	0.0276	CrCrCtD
Medrysone—Flurandrenolide—Prednisolone—hematologic cancer	0.00398	0.0249	CrCrCtD
Medrysone—Hydrocortamate—Prednisone—hematologic cancer	0.00382	0.0239	CrCrCtD
Medrysone—Fluocortolone—Betamethasone—hematologic cancer	0.00376	0.0235	CrCrCtD
Medrysone—Fluocortolone—Dexamethasone—hematologic cancer	0.00376	0.0235	CrCrCtD
Medrysone—Hydrocortamate—Prednisolone—hematologic cancer	0.00373	0.0233	CrCrCtD
Medrysone—Cortisone acetate—Prednisone—hematologic cancer	0.0037	0.0232	CrCrCtD
Medrysone—Fluocortolone—Triamcinolone—hematologic cancer	0.00367	0.023	CrCrCtD
Medrysone—Cortisone acetate—Prednisolone—hematologic cancer	0.00361	0.0226	CrCrCtD
Medrysone—Fluocortolone—Prednisone—hematologic cancer	0.00349	0.0218	CrCrCtD
Medrysone—Fluocortolone—Prednisolone—hematologic cancer	0.0034	0.0213	CrCrCtD
Medrysone—Paramethasone—Dexamethasone—hematologic cancer	0.00338	0.0212	CrCrCtD
Medrysone—Paramethasone—Betamethasone—hematologic cancer	0.00338	0.0212	CrCrCtD
Medrysone—Paramethasone—Triamcinolone—hematologic cancer	0.0033	0.0207	CrCrCtD
Medrysone—Loteprednol—Betamethasone—hematologic cancer	0.00322	0.0202	CrCrCtD
Medrysone—Loteprednol—Dexamethasone—hematologic cancer	0.00322	0.0202	CrCrCtD
Medrysone—Fluorometholone—Dexamethasone—hematologic cancer	0.00322	0.0202	CrCrCtD
Medrysone—Fluorometholone—Betamethasone—hematologic cancer	0.00322	0.0202	CrCrCtD
Medrysone—Rimexolone—Dexamethasone—hematologic cancer	0.00314	0.0197	CrCrCtD
Medrysone—Rimexolone—Betamethasone—hematologic cancer	0.00314	0.0197	CrCrCtD
Medrysone—Loteprednol—Triamcinolone—hematologic cancer	0.00314	0.0197	CrCrCtD
Medrysone—Fluorometholone—Triamcinolone—hematologic cancer	0.00314	0.0197	CrCrCtD
Medrysone—Progesterone—Prednisolone—hematologic cancer	0.00314	0.0196	CrCrCtD
Medrysone—Methyltestosterone—Prednisone—hematologic cancer	0.00313	0.0196	CrCrCtD
Medrysone—Paramethasone—Prednisone—hematologic cancer	0.00313	0.0196	CrCrCtD
Medrysone—Rimexolone—Triamcinolone—hematologic cancer	0.00307	0.0192	CrCrCtD
Medrysone—Paramethasone—Prednisolone—hematologic cancer	0.00306	0.0192	CrCrCtD
Medrysone—Methyltestosterone—Prednisolone—hematologic cancer	0.00306	0.0192	CrCrCtD
Medrysone—Methylprednisolone—Dexamethasone—hematologic cancer	0.00301	0.0188	CrCrCtD
Medrysone—Methylprednisolone—Betamethasone—hematologic cancer	0.00301	0.0188	CrCrCtD
Medrysone—Fluorometholone—Prednisone—hematologic cancer	0.00298	0.0187	CrCrCtD
Medrysone—Loteprednol—Prednisone—hematologic cancer	0.00298	0.0187	CrCrCtD
Medrysone—Prednisolone—Dexamethasone—hematologic cancer	0.00294	0.0184	CrCrCtD
Medrysone—Prednisolone—Betamethasone—hematologic cancer	0.00294	0.0184	CrCrCtD
Medrysone—Methylprednisolone—Triamcinolone—hematologic cancer	0.00294	0.0184	CrCrCtD
Medrysone—Rimexolone—Prednisone—hematologic cancer	0.00292	0.0183	CrCrCtD
Medrysone—Loteprednol—Prednisolone—hematologic cancer	0.00291	0.0182	CrCrCtD
Medrysone—Fluorometholone—Prednisolone—hematologic cancer	0.00291	0.0182	CrCrCtD
Medrysone—Prednisolone—Triamcinolone—hematologic cancer	0.00288	0.018	CrCrCtD
Medrysone—Rimexolone—Prednisolone—hematologic cancer	0.00285	0.0178	CrCrCtD
Medrysone—Hydrocortisone—Dexamethasone—hematologic cancer	0.00283	0.0177	CrCrCtD
Medrysone—Hydrocortisone—Betamethasone—hematologic cancer	0.00283	0.0177	CrCrCtD
Medrysone—Methylprednisolone—Prednisone—hematologic cancer	0.00279	0.0175	CrCrCtD
Medrysone—Hydrocortisone—Triamcinolone—hematologic cancer	0.00276	0.0173	CrCrCtD
Medrysone—Prednisolone—Prednisone—hematologic cancer	0.00273	0.0171	CrCrCtD
Medrysone—Methylprednisolone—Prednisolone—hematologic cancer	0.00272	0.0171	CrCrCtD
Medrysone—Testosterone—Prednisolone—hematologic cancer	0.00272	0.0171	CrCrCtD
Medrysone—Hydrocortisone—Prednisone—hematologic cancer	0.00262	0.0164	CrCrCtD
Medrysone—Hydrocortisone—Prednisolone—hematologic cancer	0.00256	0.016	CrCrCtD
Medrysone—Anterior uveitis—Prednisolone—hematologic cancer	0.00121	0.0362	CcSEcCtD
Medrysone—Posterior subcapsular cataract—Prednisolone—hematologic cancer	0.000735	0.0221	CcSEcCtD
Medrysone—Hyperadrenocorticism—Prednisolone—hematologic cancer	0.000735	0.0221	CcSEcCtD
Medrysone—Iridocyclitis—Prednisolone—hematologic cancer	0.000692	0.0208	CcSEcCtD
Medrysone—Hyperadrenocorticism—Triamcinolone—hematologic cancer	0.000676	0.0203	CcSEcCtD
Medrysone—Posterior subcapsular cataract—Dexamethasone—hematologic cancer	0.000613	0.0184	CcSEcCtD
Medrysone—Posterior subcapsular cataract—Betamethasone—hematologic cancer	0.000613	0.0184	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—RFXANK—hematologic cancer	0.000561	0.0406	CbGpPWpGaD
Medrysone—Sensation of foreign body—Bortezomib—hematologic cancer	0.000528	0.0159	CcSEcCtD
Medrysone—Nerve injury—Prednisolone—hematologic cancer	0.000521	0.0156	CcSEcCtD
Medrysone—Ulcerative keratitis—Prednisolone—hematologic cancer	0.00045	0.0135	CcSEcCtD
Medrysone—Impaired healing—Melphalan—hematologic cancer	0.000445	0.0134	CcSEcCtD
Medrysone—Cataract subcapsular—Prednisolone—hematologic cancer	0.000435	0.0131	CcSEcCtD
Medrysone—Nerve injury—Betamethasone—hematologic cancer	0.000434	0.0131	CcSEcCtD
Medrysone—Nerve injury—Dexamethasone—hematologic cancer	0.000434	0.0131	CcSEcCtD
Medrysone—Impaired healing—Lenalidomide—hematologic cancer	0.000432	0.013	CcSEcCtD
Medrysone—Cataract subcapsular—Triamcinolone—hematologic cancer	0.0004	0.012	CcSEcCtD
Medrysone—Impaired healing—Bortezomib—hematologic cancer	0.000398	0.012	CcSEcCtD
Medrysone—Nerve injury—Prednisone—hematologic cancer	0.000378	0.0114	CcSEcCtD
Medrysone—Eye infection—Prednisolone—hematologic cancer	0.000367	0.011	CcSEcCtD
Medrysone—Cataract subcapsular—Betamethasone—hematologic cancer	0.000363	0.0109	CcSEcCtD
Medrysone—Cataract subcapsular—Dexamethasone—hematologic cancer	0.000363	0.0109	CcSEcCtD
Medrysone—Keratitis—Bexarotene—hematologic cancer	0.00036	0.0108	CcSEcCtD
Medrysone—Sensation of foreign body—Prednisolone—hematologic cancer	0.000349	0.0105	CcSEcCtD
Medrysone—Impaired healing—Carmustine—hematologic cancer	0.000345	0.0104	CcSEcCtD
Medrysone—Impaired healing—Alitretinoin—hematologic cancer	0.000341	0.0103	CcSEcCtD
Medrysone—Ulcerative keratitis—Prednisone—hematologic cancer	0.000327	0.00982	CcSEcCtD
Medrysone—Cataract subcapsular—Prednisone—hematologic cancer	0.000316	0.00951	CcSEcCtD
Medrysone—Viral infection—Daunorubicin—hematologic cancer	0.000314	0.00944	CcSEcCtD
Medrysone—Viral infection—Clofarabine—hematologic cancer	0.000314	0.00944	CcSEcCtD
Medrysone—Viral infection—Pentostatin—hematologic cancer	0.000313	0.00939	CcSEcCtD
Medrysone—Eye infection—Betamethasone—hematologic cancer	0.000306	0.00919	CcSEcCtD
Medrysone—Eye infection—Dexamethasone—hematologic cancer	0.000306	0.00919	CcSEcCtD
Medrysone—Sensation of foreign body—Dexamethasone—hematologic cancer	0.000291	0.00874	CcSEcCtD
Medrysone—Sensation of foreign body—Betamethasone—hematologic cancer	0.000291	0.00874	CcSEcCtD
Medrysone—Visual disturbance—Lomustine—hematologic cancer	0.000287	0.00863	CcSEcCtD
Medrysone—Glaucoma—Imatinib—hematologic cancer	0.000285	0.00856	CcSEcCtD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PER2—hematologic cancer	0.00028	0.0203	CbGpPWpGaD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CRY2—hematologic cancer	0.00028	0.0203	CbGpPWpGaD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CRY1—hematologic cancer	0.00028	0.0203	CbGpPWpGaD
Medrysone—SERPINA6—hematopoietic system—hematologic cancer	0.00028	0.204	CbGeAlD
Medrysone—Impaired healing—Prednisolone—hematologic cancer	0.000263	0.0079	CcSEcCtD
Medrysone—Viral infection—Bexarotene—hematologic cancer	0.000258	0.00777	CcSEcCtD
Medrysone—Conjunctival hyperaemia—Prednisolone—hematologic cancer	0.000258	0.00776	CcSEcCtD
Medrysone—Eye irritation—Nilotinib—hematologic cancer	0.000253	0.00759	CcSEcCtD
Medrysone—Eye irritation—Imatinib—hematologic cancer	0.000251	0.00755	CcSEcCtD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—CEBPA—hematologic cancer	0.000244	0.0176	CbGpPWpGaD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—CEBPD—hematologic cancer	0.000244	0.0176	CbGpPWpGaD
Medrysone—Impaired healing—Triamcinolone—hematologic cancer	0.000242	0.00726	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—HDAC11—hematologic cancer	0.000233	0.0169	CbGpPWpGaD
Medrysone—Keratitis—Alitretinoin—hematologic cancer	0.000228	0.00684	CcSEcCtD
Medrysone—Impaired healing—Betamethasone—hematologic cancer	0.000219	0.00659	CcSEcCtD
Medrysone—Impaired healing—Dexamethasone—hematologic cancer	0.000219	0.00659	CcSEcCtD
Medrysone—Eye irritation—Lenalidomide—hematologic cancer	0.000219	0.00658	CcSEcCtD
Medrysone—Conjunctival hyperaemia—Betamethasone—hematologic cancer	0.000216	0.00648	CcSEcCtD
Medrysone—Conjunctival hyperaemia—Dexamethasone—hematologic cancer	0.000216	0.00648	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—GATA2—hematologic cancer	0.000215	0.0156	CbGpPWpGaD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PER1—hematologic cancer	0.000212	0.0153	CbGpPWpGaD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—HDAC10—hematologic cancer	0.000208	0.015	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—CRY1—hematologic cancer	0.000204	0.0147	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—CRY2—hematologic cancer	0.000204	0.0147	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—PER2—hematologic cancer	0.000204	0.0147	CbGpPWpGaD
Medrysone—Eye irritation—Bortezomib—hematologic cancer	0.000201	0.00605	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—BCL6—hematologic cancer	0.000195	0.0141	CbGpPWpGaD
Medrysone—Impaired healing—Prednisone—hematologic cancer	0.000191	0.00574	CcSEcCtD
Medrysone—Viral infection—Bortezomib—hematologic cancer	0.00019	0.00572	CcSEcCtD
Medrysone—SERPINA6—blood—hematologic cancer	0.000185	0.135	CbGeAlD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—GATA1—hematologic cancer	0.000185	0.0134	CbGpPWpGaD
Medrysone—Stinging—Alitretinoin—hematologic cancer	0.000182	0.00547	CcSEcCtD
Medrysone—Visual impairment—Lomustine—hematologic cancer	0.000182	0.00545	CcSEcCtD
Medrysone—SERPINA6—bone marrow—hematologic cancer	0.000179	0.131	CbGeAlD
Medrysone—Visual disturbance—Dasatinib—hematologic cancer	0.000179	0.00537	CcSEcCtD
Medrysone—Visual disturbance—Fludarabine—hematologic cancer	0.000178	0.00536	CcSEcCtD
Medrysone—Keratitis—Prednisolone—hematologic cancer	0.000175	0.00526	CcSEcCtD
Medrysone—Eye irritation—Alitretinoin—hematologic cancer	0.000173	0.00519	CcSEcCtD
Medrysone—Viral infection—Thalidomide—hematologic cancer	0.000172	0.00516	CcSEcCtD
Medrysone—Eye irritation—Ifosfamide—hematologic cancer	0.000171	0.00513	CcSEcCtD
Medrysone—NR3C1—Nuclear Receptors—RARA—hematologic cancer	0.000169	0.0122	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—GATA2—hematologic cancer	0.000165	0.0119	CbGpPWpGaD
Medrysone—SERPINA6—lung—hematologic cancer	0.000162	0.119	CbGeAlD
Medrysone—Impaired healing—Methotrexate—hematologic cancer	0.00016	0.00479	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—PBX1—hematologic cancer	0.000159	0.0115	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—PER1—hematologic cancer	0.000155	0.0112	CbGpPWpGaD
Medrysone—Conjunctivitis—Daunorubicin—hematologic cancer	0.000154	0.00463	CcSEcCtD
Medrysone—Conjunctivitis—Anagrelide—hematologic cancer	0.000154	0.00461	CcSEcCtD
Medrysone—Conjunctivitis—Pentostatin—hematologic cancer	0.000154	0.00461	CcSEcCtD
Medrysone—NR3C1—Endoderm Differentiation—DUSP5—hematologic cancer	0.000153	0.0111	CbGpPWpGaD
Medrysone—Viral infection—Mitoxantrone—hematologic cancer	0.000153	0.00461	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—hematologic cancer	0.000152	0.011	CbGpPWpGaD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—ARNTL—hematologic cancer	0.000151	0.0109	CbGpPWpGaD
Medrysone—Glaucoma—Prednisolone—hematologic cancer	0.000151	0.00453	CcSEcCtD
Medrysone—NR3C1—AP-1 transcription factor network—CBFB—hematologic cancer	0.00015	0.0108	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—MAF—hematologic cancer	0.00015	0.0108	CbGpPWpGaD
Medrysone—Keratitis—Betamethasone—hematologic cancer	0.000146	0.00439	CcSEcCtD
Medrysone—Keratitis—Dexamethasone—hematologic cancer	0.000146	0.00439	CcSEcCtD
Medrysone—Visual disturbance—Lenalidomide—hematologic cancer	0.000143	0.0043	CcSEcCtD
Medrysone—Mydriasis—Prednisolone—hematologic cancer	0.000142	0.00428	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—NCOR2—hematologic cancer	0.000142	0.0103	CbGpPWpGaD
Medrysone—Stinging—Prednisolone—hematologic cancer	0.00014	0.00421	CcSEcCtD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CEBPA—hematologic cancer	0.00014	0.0101	CbGpPWpGaD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CEBPD—hematologic cancer	0.00014	0.0101	CbGpPWpGaD
Medrysone—Glaucoma—Triamcinolone—hematologic cancer	0.000139	0.00417	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.000137	0.00994	CbGpPWpGaD
Medrysone—Visual impairment—Daunorubicin—hematologic cancer	0.000137	0.00412	CcSEcCtD
Medrysone—Visual impairment—Anagrelide—hematologic cancer	0.000137	0.00411	CcSEcCtD
Medrysone—Visual impairment—Pentostatin—hematologic cancer	0.000137	0.00411	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—SUMO1—hematologic cancer	0.000134	0.00968	CbGpPWpGaD
Medrysone—NR3C1—Nuclear Receptor transcription pathway—RARA—hematologic cancer	0.000134	0.00968	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CBFB—hematologic cancer	0.000133	0.00964	CbGpPWpGaD
Medrysone—Eye irritation—Prednisolone—hematologic cancer	0.000133	0.004	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—SPI1—hematologic cancer	0.000132	0.00955	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—GATA2—hematologic cancer	0.000132	0.00954	CbGpPWpGaD
Medrysone—NR3C1—Endoderm Differentiation—EOMES—hematologic cancer	0.00013	0.00943	CbGpPWpGaD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—HDAC9—hematologic cancer	0.00013	0.00938	CbGpPWpGaD
Medrysone—Stinging—Triamcinolone—hematologic cancer	0.000129	0.00388	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—TCF3—hematologic cancer	0.000127	0.0092	CbGpPWpGaD
Medrysone—Conjunctivitis—Dasatinib—hematologic cancer	0.000127	0.00381	CcSEcCtD
Medrysone—Conjunctivitis—Bexarotene—hematologic cancer	0.000127	0.00381	CcSEcCtD
Medrysone—Glaucoma—Dexamethasone—hematologic cancer	0.000126	0.00378	CcSEcCtD
Medrysone—Glaucoma—Betamethasone—hematologic cancer	0.000126	0.00378	CcSEcCtD
Medrysone—Viral infection—Prednisolone—hematologic cancer	0.000126	0.00378	CcSEcCtD
Medrysone—Vision blurred—Nelarabine—hematologic cancer	0.000125	0.00375	CcSEcCtD
Medrysone—NR3C1—Nuclear Receptor transcription pathway—NR0B2—hematologic cancer	0.000124	0.009	CbGpPWpGaD
Medrysone—NR3C1—hematopoietic system—hematologic cancer	0.000122	0.0895	CbGeAlD
Medrysone—NR3C1—Regulation of Androgen receptor activity—CEBPA—hematologic cancer	0.000121	0.00872	CbGpPWpGaD
Medrysone—Visual disturbance—Thalidomide—hematologic cancer	0.000119	0.00357	CcSEcCtD
Medrysone—Conjunctivitis—Nilotinib—hematologic cancer	0.000117	0.00352	CcSEcCtD
Medrysone—Stinging—Dexamethasone—hematologic cancer	0.000117	0.00352	CcSEcCtD
Medrysone—Stinging—Betamethasone—hematologic cancer	0.000117	0.00352	CcSEcCtD
Medrysone—Conjunctivitis—Imatinib—hematologic cancer	0.000117	0.0035	CcSEcCtD
Medrysone—Vision blurred—Anagrelide—hematologic cancer	0.000116	0.0035	CcSEcCtD
Medrysone—Conjunctivitis—Cladribine—hematologic cancer	0.000115	0.00344	CcSEcCtD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NF1—hematologic cancer	0.000114	0.00825	CbGpPWpGaD
Medrysone—Visual disturbance—Alitretinoin—hematologic cancer	0.000113	0.0034	CcSEcCtD
Medrysone—Visual impairment—Dasatinib—hematologic cancer	0.000113	0.00339	CcSEcCtD
Medrysone—Visual impairment—Fludarabine—hematologic cancer	0.000113	0.00339	CcSEcCtD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—NUP214—hematologic cancer	0.000111	0.00806	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—ARNTL—hematologic cancer	0.00011	0.00796	CbGpPWpGaD
Medrysone—Glaucoma—Prednisone—hematologic cancer	0.00011	0.0033	CcSEcCtD
Medrysone—Visual disturbance—Irinotecan—hematologic cancer	0.000106	0.00319	CcSEcCtD
Medrysone—Visual impairment—Nilotinib—hematologic cancer	0.000104	0.00314	CcSEcCtD
Medrysone—NR3C1—Adipogenesis—EBF1—hematologic cancer	0.000102	0.00741	CbGpPWpGaD
Medrysone—Conjunctivitis—Lenalidomide—hematologic cancer	0.000102	0.00305	CcSEcCtD
Medrysone—NR3C1—Endoderm Differentiation—LEF1—hematologic cancer	0.000101	0.00727	CbGpPWpGaD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—hematologic cancer	9.98e-05	0.00721	CbGpPWpGaD
Medrysone—Keratitis—Epirubicin—hematologic cancer	9.96e-05	0.00299	CcSEcCtD
Medrysone—Vision blurred—Dasatinib—hematologic cancer	9.62e-05	0.00289	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—PBX1—hematologic cancer	9.53e-05	0.00689	CbGpPWpGaD
Medrysone—Hypersensitivity—Mechlorethamine—hematologic cancer	9.44e-05	0.00284	CcSEcCtD
Medrysone—Conjunctivitis—Bortezomib—hematologic cancer	9.35e-05	0.00281	CcSEcCtD
Medrysone—NR3C1—gonad—hematologic cancer	9.31e-05	0.068	CbGeAlD
Medrysone—Pain—Nelarabine—hematologic cancer	9.25e-05	0.00278	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—hematologic cancer	9.24e-05	0.00668	CbGpPWpGaD
Medrysone—Keratitis—Doxorubicin—hematologic cancer	9.21e-05	0.00277	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—SGK1—hematologic cancer	9.15e-05	0.00662	CbGpPWpGaD
Medrysone—Viral infection—Prednisone—hematologic cancer	9.14e-05	0.00275	CcSEcCtD
Medrysone—Drostanolone—AR—hematologic cancer	9.09e-05	0.0741	CrCbGaD
Medrysone—Visual impairment—Lenalidomide—hematologic cancer	9.05e-05	0.00272	CcSEcCtD
Medrysone—Vision blurred—Nilotinib—hematologic cancer	8.89e-05	0.00267	CcSEcCtD
Medrysone—NR3C1—Regulation of Androgen receptor activity—REL—hematologic cancer	8.85e-05	0.0064	CbGpPWpGaD
Medrysone—Vision blurred—Imatinib—hematologic cancer	8.84e-05	0.00266	CcSEcCtD
Medrysone—Conjunctivitis—Thiotepa—hematologic cancer	8.72e-05	0.00262	CcSEcCtD
Medrysone—NR3C1—Adipogenesis—ID3—hematologic cancer	8.71e-05	0.0063	CbGpPWpGaD
Medrysone—Visual disturbance—Prednisolone—hematologic cancer	8.71e-05	0.00262	CcSEcCtD
Medrysone—Pain—Daunorubicin—hematologic cancer	8.65e-05	0.0026	CcSEcCtD
Medrysone—Pain—Clofarabine—hematologic cancer	8.65e-05	0.0026	CcSEcCtD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—hematologic cancer	8.65e-05	0.00626	CbGpPWpGaD
Medrysone—Pain—Anagrelide—hematologic cancer	8.61e-05	0.00259	CcSEcCtD
Medrysone—Pain—Pentostatin—hematologic cancer	8.61e-05	0.00259	CcSEcCtD
Medrysone—Conjunctivitis—Thalidomide—hematologic cancer	8.44e-05	0.00253	CcSEcCtD
Medrysone—Visual impairment—Bortezomib—hematologic cancer	8.32e-05	0.0025	CcSEcCtD
Medrysone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—hematologic cancer	8.14e-05	0.00588	CbGpPWpGaD
Medrysone—NR3C1—blood—hematologic cancer	8.11e-05	0.0593	CbGeAlD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—HSP90AA1—hematologic cancer	8.11e-05	0.00587	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—GATA2—hematologic cancer	8.04e-05	0.00581	CbGpPWpGaD
Medrysone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—hematologic cancer	8.03e-05	0.00581	CbGpPWpGaD
Medrysone—Conjunctivitis—Alitretinoin—hematologic cancer	8.03e-05	0.00241	CcSEcCtD
Medrysone—Stinging—Epirubicin—hematologic cancer	7.97e-05	0.0024	CcSEcCtD
Medrysone—Conjunctivitis—Ifosfamide—hematologic cancer	7.93e-05	0.00238	CcSEcCtD
Medrysone—NR3C1—bone marrow—hematologic cancer	7.85e-05	0.0574	CbGeAlD
Medrysone—Hypersensitivity—Methoxsalen—hematologic cancer	7.78e-05	0.00234	CcSEcCtD
Medrysone—Testosterone Propionate—UGT1A1—hematologic cancer	7.75e-05	0.0632	CrCbGaD
Medrysone—NR3C1—AP-1 transcription factor network—JUND—hematologic cancer	7.72e-05	0.00558	CbGpPWpGaD
Medrysone—Vision blurred—Lenalidomide—hematologic cancer	7.7e-05	0.00231	CcSEcCtD
Medrysone—NR3C1—AP-1 transcription factor network—MYB—hematologic cancer	7.58e-05	0.00548	CbGpPWpGaD
Medrysone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAP2K1—hematologic cancer	7.56e-05	0.00547	CbGpPWpGaD
Medrysone—NR3C1—Nuclear Receptors—AR—hematologic cancer	7.56e-05	0.00547	CbGpPWpGaD
Medrysone—Hypersensitivity—Mercaptopurine—hematologic cancer	7.56e-05	0.00227	CcSEcCtD
Medrysone—Conjunctivitis—Mitoxantrone—hematologic cancer	7.53e-05	0.00226	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—TCF3—hematologic cancer	7.53e-05	0.00545	CbGpPWpGaD
Medrysone—Visual impairment—Thalidomide—hematologic cancer	7.51e-05	0.00226	CcSEcCtD
Medrysone—Pain—Busulfan—hematologic cancer	7.49e-05	0.00225	CcSEcCtD
Medrysone—Hypersensitivity—Daunorubicin—hematologic cancer	7.46e-05	0.00224	CcSEcCtD
Medrysone—Hypersensitivity—Clofarabine—hematologic cancer	7.46e-05	0.00224	CcSEcCtD
Medrysone—Hypersensitivity—Pentostatin—hematologic cancer	7.42e-05	0.00223	CcSEcCtD
Medrysone—Stinging—Doxorubicin—hematologic cancer	7.38e-05	0.00222	CcSEcCtD
Medrysone—NR3C1—Endoderm Differentiation—DKK1—hematologic cancer	7.31e-05	0.00529	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—hematologic cancer	7.31e-05	0.00528	CbGpPWpGaD
Medrysone—Pain—Procarbazine—hematologic cancer	7.27e-05	0.00218	CcSEcCtD
Medrysone—Visual disturbance—Betamethasone—hematologic cancer	7.26e-05	0.00218	CcSEcCtD
Medrysone—Visual disturbance—Dexamethasone—hematologic cancer	7.26e-05	0.00218	CcSEcCtD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—CREB1—hematologic cancer	7.24e-05	0.00523	CbGpPWpGaD
Medrysone—Visual impairment—Carmustine—hematologic cancer	7.21e-05	0.00217	CcSEcCtD
Medrysone—Hypersensitivity—Idarubicin—hematologic cancer	7.16e-05	0.00215	CcSEcCtD
Medrysone—Viral infection—Epirubicin—hematologic cancer	7.15e-05	0.00215	CcSEcCtD
Medrysone—Visual impairment—Alitretinoin—hematologic cancer	7.14e-05	0.00215	CcSEcCtD
Medrysone—Pain—Dasatinib—hematologic cancer	7.12e-05	0.00214	CcSEcCtD
Medrysone—Pain—Bexarotene—hematologic cancer	7.12e-05	0.00214	CcSEcCtD
Medrysone—NR3C1—lung—hematologic cancer	7.11e-05	0.052	CbGeAlD
Medrysone—Pain—Fludarabine—hematologic cancer	7.1e-05	0.00213	CcSEcCtD
Medrysone—Vision blurred—Bortezomib—hematologic cancer	7.09e-05	0.00213	CcSEcCtD
Medrysone—Visual impairment—Ifosfamide—hematologic cancer	7.06e-05	0.00212	CcSEcCtD
Medrysone—Hypersensitivity—Teniposide—hematologic cancer	6.96e-05	0.00209	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—GATA2—hematologic cancer	6.95e-05	0.00503	CbGpPWpGaD
Medrysone—Conjunctivitis—Cisplatin—hematologic cancer	6.84e-05	0.00205	CcSEcCtD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—hematologic cancer	6.75e-05	0.00488	CbGpPWpGaD
Medrysone—Pain—Chlorambucil—hematologic cancer	6.73e-05	0.00202	CcSEcCtD
Medrysone—NR3C1—testis—hematologic cancer	6.71e-05	0.049	CbGeAlD
Medrysone—Visual impairment—Irinotecan—hematologic cancer	6.7e-05	0.00201	CcSEcCtD
Medrysone—Viral infection—Doxorubicin—hematologic cancer	6.62e-05	0.00199	CcSEcCtD
Medrysone—Vision blurred—Thiotepa—hematologic cancer	6.61e-05	0.00199	CcSEcCtD
Medrysone—Drospirenone—AR—hematologic cancer	6.6e-05	0.0539	CrCbGaD
Medrysone—Pain—Nilotinib—hematologic cancer	6.58e-05	0.00198	CcSEcCtD
Medrysone—Pain—Imatinib—hematologic cancer	6.54e-05	0.00197	CcSEcCtD
Medrysone—Hypersensitivity—Busulfan—hematologic cancer	6.45e-05	0.00194	CcSEcCtD
Medrysone—Pain—Cladribine—hematologic cancer	6.43e-05	0.00193	CcSEcCtD
Medrysone—Vision blurred—Thalidomide—hematologic cancer	6.39e-05	0.00192	CcSEcCtD
Medrysone—NR3C1—Endoderm Differentiation—PTHLH—hematologic cancer	6.37e-05	0.00461	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—RARA—hematologic cancer	6.33e-05	0.00458	CbGpPWpGaD
Medrysone—Loteprednol—NR3C1—hematologic cancer	6.31e-05	0.0514	CrCbGaD
Medrysone—Hypersensitivity—Procarbazine—hematologic cancer	6.26e-05	0.00188	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—STAT5B—hematologic cancer	6.25e-05	0.00452	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—HSP90AA1—hematologic cancer	6.22e-05	0.00449	CbGpPWpGaD
Medrysone—Conjunctivitis—Prednisolone—hematologic cancer	6.18e-05	0.00186	CcSEcCtD
Medrysone—Pain—Vinblastine—hematologic cancer	6.17e-05	0.00185	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—RET—hematologic cancer	6.14e-05	0.00444	CbGpPWpGaD
Medrysone—Vision blurred—Carmustine—hematologic cancer	6.14e-05	0.00184	CcSEcCtD
Medrysone—Hypersensitivity—Dasatinib—hematologic cancer	6.14e-05	0.00184	CcSEcCtD
Medrysone—Hypersensitivity—Bexarotene—hematologic cancer	6.14e-05	0.00184	CcSEcCtD
Medrysone—Hypersensitivity—Fludarabine—hematologic cancer	6.12e-05	0.00184	CcSEcCtD
Medrysone—Visual impairment—Cisplatin—hematologic cancer	6.09e-05	0.00183	CcSEcCtD
Medrysone—Vision blurred—Alitretinoin—hematologic cancer	6.08e-05	0.00183	CcSEcCtD
Medrysone—Vision blurred—Ifosfamide—hematologic cancer	6.01e-05	0.00181	CcSEcCtD
Medrysone—NR3C1—Nuclear Receptor transcription pathway—AR—hematologic cancer	5.98e-05	0.00432	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—CEBPD—hematologic cancer	5.89e-05	0.00426	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—CEBPA—hematologic cancer	5.89e-05	0.00426	CbGpPWpGaD
Medrysone—Pain—Melphalan—hematologic cancer	5.87e-05	0.00176	CcSEcCtD
Medrysone—NR3C1—Generic Transcription Pathway—ZNF552—hematologic cancer	5.81e-05	0.0042	CbGpPWpGaD
Medrysone—NR3C1—Endoderm Differentiation—EZH2—hematologic cancer	5.8e-05	0.00419	CbGpPWpGaD
Medrysone—Hypersensitivity—Chlorambucil—hematologic cancer	5.8e-05	0.00174	CcSEcCtD
Medrysone—NR3C1—Regulation of Androgen receptor activity—AR—hematologic cancer	5.8e-05	0.00419	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—hematologic cancer	5.75e-05	0.00416	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—IL13—hematologic cancer	5.71e-05	0.00413	CbGpPWpGaD
Medrysone—Vision blurred—Mitoxantrone—hematologic cancer	5.71e-05	0.00171	CcSEcCtD
Medrysone—Pain—Lenalidomide—hematologic cancer	5.7e-05	0.00171	CcSEcCtD
Medrysone—Conjunctivitis—Triamcinolone—hematologic cancer	5.68e-05	0.00171	CcSEcCtD
Medrysone—Hypersensitivity—Nilotinib—hematologic cancer	5.67e-05	0.0017	CcSEcCtD
Medrysone—Hypersensitivity—Imatinib—hematologic cancer	5.64e-05	0.00169	CcSEcCtD
Medrysone—Pain—Hydroxyurea—hematologic cancer	5.62e-05	0.00169	CcSEcCtD
Medrysone—Flurandrenolide—NR3C1—hematologic cancer	5.59e-05	0.0456	CrCbGaD
Medrysone—Testosterone Propionate—AR—hematologic cancer	5.54e-05	0.0452	CrCbGaD
Medrysone—Hypersensitivity—Cladribine—hematologic cancer	5.54e-05	0.00166	CcSEcCtD
Medrysone—Visual impairment—Prednisolone—hematologic cancer	5.5e-05	0.00165	CcSEcCtD
Medrysone—Hydrocortamate—NR3C1—hematologic cancer	5.4e-05	0.0441	CrCbGaD
Medrysone—Cortisone acetate—NR3C1—hematologic cancer	5.32e-05	0.0434	CrCbGaD
Medrysone—NR3C1—Adipogenesis—NCOR2—hematologic cancer	5.31e-05	0.00384	CbGpPWpGaD
Medrysone—Hypersensitivity—Vinblastine—hematologic cancer	5.31e-05	0.0016	CcSEcCtD
Medrysone—Visual disturbance—Methotrexate—hematologic cancer	5.29e-05	0.00159	CcSEcCtD
Medrysone—Pain—Bortezomib—hematologic cancer	5.25e-05	0.00158	CcSEcCtD
Medrysone—Pain—Bleomycin—hematologic cancer	5.21e-05	0.00156	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—GATA3—hematologic cancer	5.21e-05	0.00376	CbGpPWpGaD
Medrysone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—hematologic cancer	5.19e-05	0.00376	CbGpPWpGaD
Medrysone—NR3C1—Nuclear Receptors—ESR1—hematologic cancer	5.19e-05	0.00376	CbGpPWpGaD
Medrysone—Vision blurred—Cisplatin—hematologic cancer	5.18e-05	0.00156	CcSEcCtD
Medrysone—Conjunctivitis—Betamethasone—hematologic cancer	5.16e-05	0.00155	CcSEcCtD
Medrysone—Conjunctivitis—Dexamethasone—hematologic cancer	5.16e-05	0.00155	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—GATA3—hematologic cancer	5.16e-05	0.00373	CbGpPWpGaD
Medrysone—Megestrol acetate—NR3C1—hematologic cancer	5.13e-05	0.0418	CrCbGaD
Medrysone—Pain—Vinorelbine—hematologic cancer	5.12e-05	0.00154	CcSEcCtD
Medrysone—Hypersensitivity—Melphalan—hematologic cancer	5.05e-05	0.00152	CcSEcCtD
Medrysone—NR3C1—Regulation of Androgen receptor activity—FOXO1—hematologic cancer	4.94e-05	0.00357	CbGpPWpGaD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—MAPK8—hematologic cancer	4.92e-05	0.00356	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—NCOR1—hematologic cancer	4.92e-05	0.00356	CbGpPWpGaD
Medrysone—Hypersensitivity—Lenalidomide—hematologic cancer	4.91e-05	0.00148	CcSEcCtD
Medrysone—NR3C1—Endoderm Differentiation—STAT1—hematologic cancer	4.91e-05	0.00355	CbGpPWpGaD
Medrysone—Pain—Thiotepa—hematologic cancer	4.89e-05	0.00147	CcSEcCtD
Medrysone—NR3C1—lymph node—hematologic cancer	4.86e-05	0.0355	CbGeAlD
Medrysone—Hypersensitivity—Hydroxyurea—hematologic cancer	4.84e-05	0.00146	CcSEcCtD
Medrysone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—hematologic cancer	4.84e-05	0.0035	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—HDAC2—hematologic cancer	4.76e-05	0.00344	CbGpPWpGaD
Medrysone—Pain—Thalidomide—hematologic cancer	4.73e-05	0.00142	CcSEcCtD
Medrysone—Rimexolone—NR3C1—hematologic cancer	4.72e-05	0.0385	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—HDAC2—hematologic cancer	4.72e-05	0.00341	CbGpPWpGaD
Medrysone—Vision blurred—Prednisolone—hematologic cancer	4.68e-05	0.00141	CcSEcCtD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—hematologic cancer	4.65e-05	0.00336	CbGpPWpGaD
Medrysone—Visual impairment—Dexamethasone—hematologic cancer	4.59e-05	0.00138	CcSEcCtD
Medrysone—Visual impairment—Betamethasone—hematologic cancer	4.59e-05	0.00138	CcSEcCtD
Medrysone—Pain—Carmustine—hematologic cancer	4.55e-05	0.00137	CcSEcCtD
Medrysone—Hypersensitivity—Bortezomib—hematologic cancer	4.52e-05	0.00136	CcSEcCtD
Medrysone—Pain—Alitretinoin—hematologic cancer	4.5e-05	0.00135	CcSEcCtD
Medrysone—Hypersensitivity—Bleomycin—hematologic cancer	4.49e-05	0.00135	CcSEcCtD
Medrysone—Pain—Ifosfamide—hematologic cancer	4.45e-05	0.00134	CcSEcCtD
Medrysone—Hypersensitivity—Vinorelbine—hematologic cancer	4.41e-05	0.00133	CcSEcCtD
Medrysone—Medroxyprogesterone Acetate—AR—hematologic cancer	4.41e-05	0.0359	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—HSP90AA1—hematologic cancer	4.38e-05	0.00317	CbGpPWpGaD
Medrysone—Pain—Vincristine—hematologic cancer	4.34e-05	0.0013	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	4.33e-05	0.00313	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—STAT5B—hematologic cancer	4.32e-05	0.00312	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—STAT1—hematologic cancer	4.23e-05	0.00306	CbGpPWpGaD
Medrysone—Pain—Irinotecan—hematologic cancer	4.23e-05	0.00127	CcSEcCtD
Medrysone—Pain—Mitoxantrone—hematologic cancer	4.23e-05	0.00127	CcSEcCtD
Medrysone—Hypersensitivity—Thiotepa—hematologic cancer	4.22e-05	0.00127	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	4.19e-05	0.00303	CbGpPWpGaD
Medrysone—Paramethasone—NR3C1—hematologic cancer	4.16e-05	0.034	CrCbGaD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—hematologic cancer	4.16e-05	0.00301	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	4.15e-05	0.003	CbGpPWpGaD
Medrysone—Methyltestosterone—AR—hematologic cancer	4.15e-05	0.0338	CrCbGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AR—hematologic cancer	4.13e-05	0.00299	CbGpPWpGaD
Medrysone—Pain—Gemcitabine—hematologic cancer	4.12e-05	0.00124	CcSEcCtD
Medrysone—NR3C1—Nuclear Receptor transcription pathway—ESR1—hematologic cancer	4.1e-05	0.00297	CbGpPWpGaD
Medrysone—Hypersensitivity—Thalidomide—hematologic cancer	4.08e-05	0.00123	CcSEcCtD
Medrysone—Fluorometholone—NR3C1—hematologic cancer	4.06e-05	0.0331	CrCbGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—MAPK14—hematologic cancer	4.06e-05	0.00293	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—IL10—hematologic cancer	4.06e-05	0.00293	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—CSF2—hematologic cancer	4.01e-05	0.0029	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—MYB—hematologic cancer	3.99e-05	0.00289	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—IL4—hematologic cancer	3.95e-05	0.00285	CbGpPWpGaD
Medrysone—Methylprednisolone—NR3C1—hematologic cancer	3.93e-05	0.032	CrCbGaD
Medrysone—Hypersensitivity—Carmustine—hematologic cancer	3.92e-05	0.00118	CcSEcCtD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—TNF—hematologic cancer	3.9e-05	0.00282	CbGpPWpGaD
Medrysone—Hypersensitivity—Alitretinoin—hematologic cancer	3.88e-05	0.00117	CcSEcCtD
Medrysone—Pain—Cisplatin—hematologic cancer	3.84e-05	0.00115	CcSEcCtD
Medrysone—Hypersensitivity—Ifosfamide—hematologic cancer	3.83e-05	0.00115	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—hematologic cancer	3.8e-05	0.00275	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—STAT5A—hematologic cancer	3.8e-05	0.00275	CbGpPWpGaD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—hematologic cancer	3.79e-05	0.00274	CbGpPWpGaD
Medrysone—Conjunctivitis—Methotrexate—hematologic cancer	3.75e-05	0.00113	CcSEcCtD
Medrysone—Hypersensitivity—Vincristine—hematologic cancer	3.74e-05	0.00112	CcSEcCtD
Medrysone—Hypersensitivity—Irinotecan—hematologic cancer	3.64e-05	0.00109	CcSEcCtD
Medrysone—Hypersensitivity—Mitoxantrone—hematologic cancer	3.64e-05	0.00109	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—hematologic cancer	3.61e-05	0.00261	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—hematologic cancer	3.61e-05	0.00261	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—HLA-A—hematologic cancer	3.57e-05	0.00258	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—GATA3—hematologic cancer	3.57e-05	0.00258	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—CSF2—hematologic cancer	3.53e-05	0.00256	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—hematologic cancer	3.52e-05	0.00254	CbGpPWpGaD
Medrysone—Pain—Etoposide—hematologic cancer	3.52e-05	0.00106	CcSEcCtD
Medrysone—Conjunctivitis—Epirubicin—hematologic cancer	3.51e-05	0.00106	CcSEcCtD
Medrysone—NR3C1—Regulation of Androgen receptor activity—CREBBP—hematologic cancer	3.49e-05	0.00252	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—BAX—hematologic cancer	3.48e-05	0.00252	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—CREB1—hematologic cancer	3.48e-05	0.00251	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—IL4—hematologic cancer	3.48e-05	0.00251	CbGpPWpGaD
Medrysone—Pain—Prednisolone—hematologic cancer	3.47e-05	0.00104	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—IL13—hematologic cancer	3.41e-05	0.00247	CbGpPWpGaD
Medrysone—Vision blurred—Prednisone—hematologic cancer	3.4e-05	0.00102	CcSEcCtD
Medrysone—Medroxyprogesterone Acetate—ESR1—hematologic cancer	3.39e-05	0.0277	CrCbGaD
Medrysone—NR3C1—Circadian Clock—CREBBP—hematologic cancer	3.39e-05	0.00245	CbGpPWpGaD
Medrysone—Visual impairment—Methotrexate—hematologic cancer	3.34e-05	0.001	CcSEcCtD
Medrysone—Hypersensitivity—Cisplatin—hematologic cancer	3.31e-05	0.000993	CcSEcCtD
Medrysone—Conjunctivitis—Doxorubicin—hematologic cancer	3.25e-05	0.000976	CcSEcCtD
Medrysone—Pain—Triamcinolone—hematologic cancer	3.19e-05	0.000958	CcSEcCtD
Medrysone—NR3C1—AP-1 transcription factor network—ESR1—hematologic cancer	3.19e-05	0.0023	CbGpPWpGaD
Medrysone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—hematologic cancer	3.17e-05	0.00229	CbGpPWpGaD
Medrysone—NR3C1—Endoderm Differentiation—NOTCH1—hematologic cancer	3.15e-05	0.00228	CbGpPWpGaD
Medrysone—NR3C1—Transcription factor regulation in adipogenesis—IL6—hematologic cancer	3.14e-05	0.00227	CbGpPWpGaD
Medrysone—Visual impairment—Epirubicin—hematologic cancer	3.13e-05	0.000939	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—GATA3—hematologic cancer	3.08e-05	0.00223	CbGpPWpGaD
Medrysone—Hypersensitivity—Etoposide—hematologic cancer	3.03e-05	0.00091	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK2—hematologic cancer	3.01e-05	0.00218	CbGpPWpGaD
Medrysone—Medroxyprogesterone Acetate—NR3C1—hematologic cancer	2.99e-05	0.0244	CrCbGaD
Medrysone—Hypersensitivity—Prednisolone—hematologic cancer	2.99e-05	0.000898	CcSEcCtD
Medrysone—NR3C1—Regulation of Androgen receptor activity—MDM2—hematologic cancer	2.96e-05	0.00214	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—STAT1—hematologic cancer	2.92e-05	0.00211	CbGpPWpGaD
Medrysone—Pain—Betamethasone—hematologic cancer	2.89e-05	0.000869	CcSEcCtD
Medrysone—Pain—Dexamethasone—hematologic cancer	2.89e-05	0.000869	CcSEcCtD
Medrysone—Visual impairment—Doxorubicin—hematologic cancer	2.89e-05	0.000869	CcSEcCtD
Medrysone—NR3C1—AP-1 transcription factor network—FOS—hematologic cancer	2.87e-05	0.00208	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—CREB1—hematologic cancer	2.87e-05	0.00207	CbGpPWpGaD
Medrysone—Progesterone—SLC22A1—hematologic cancer	2.86e-05	0.0234	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—MAPK14—hematologic cancer	2.86e-05	0.00207	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—hematologic cancer	2.85e-05	0.00206	CbGpPWpGaD
Medrysone—Vision blurred—Methotrexate—hematologic cancer	2.84e-05	0.000854	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—hematologic cancer	2.83e-05	0.00205	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—CCL2—hematologic cancer	2.8e-05	0.00203	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—ZNF552—hematologic cancer	2.8e-05	0.00202	CbGpPWpGaD
Medrysone—Prednisolone—NR3C1—hematologic cancer	2.77e-05	0.0226	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—hematologic cancer	2.76e-05	0.002	CbGpPWpGaD
Medrysone—Hypersensitivity—Triamcinolone—hematologic cancer	2.75e-05	0.000825	CcSEcCtD
Medrysone—Testosterone—SLC22A1—hematologic cancer	2.71e-05	0.0221	CrCbGaD
Medrysone—Vision blurred—Epirubicin—hematologic cancer	2.66e-05	0.0008	CcSEcCtD
Medrysone—NR3C1—Adipogenesis—STAT5A—hematologic cancer	2.63e-05	0.0019	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—JUN—hematologic cancer	2.58e-05	0.00186	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOS—hematologic cancer	2.55e-05	0.00185	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—hematologic cancer	2.55e-05	0.00184	CbGpPWpGaD
Medrysone—Progesterone—AR—hematologic cancer	2.54e-05	0.0208	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—FOS—hematologic cancer	2.53e-05	0.00183	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—CREB1—hematologic cancer	2.53e-05	0.00183	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—hematologic cancer	2.48e-05	0.0018	CbGpPWpGaD
Medrysone—Megestrol acetate—ABCB1—hematologic cancer	2.47e-05	0.0202	CrCbGaD
Medrysone—NR3C1—Adipogenesis—NCOR1—hematologic cancer	2.47e-05	0.00179	CbGpPWpGaD
Medrysone—Vision blurred—Doxorubicin—hematologic cancer	2.46e-05	0.00074	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—hematologic cancer	2.46e-05	0.00178	CbGpPWpGaD
Medrysone—Hydrocortisone—ABCG2—hematologic cancer	2.46e-05	0.02	CrCbGaD
Medrysone—NR3C1—AP-1 transcription factor network—CDKN2A—hematologic cancer	2.45e-05	0.00177	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—AR—hematologic cancer	2.44e-05	0.00177	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—MAPK8—hematologic cancer	2.44e-05	0.00176	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—FOXO1—hematologic cancer	2.41e-05	0.00174	CbGpPWpGaD
Medrysone—Testosterone—AR—hematologic cancer	2.41e-05	0.0196	CrCbGaD
Medrysone—NR3C1—AP-1 transcription factor network—IFNG—hematologic cancer	2.38e-05	0.00172	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—EP300—hematologic cancer	2.38e-05	0.00172	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—RARA—hematologic cancer	2.31e-05	0.00167	CbGpPWpGaD
Medrysone—NR3C1—Regulation of Androgen receptor activity—SRC—hematologic cancer	2.31e-05	0.00167	CbGpPWpGaD
Medrysone—NR3C1—Circadian Clock—EP300—hematologic cancer	2.31e-05	0.00167	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—FAS—hematologic cancer	2.22e-05	0.0016	CbGpPWpGaD
Medrysone—Hypersensitivity—Prednisone—hematologic cancer	2.17e-05	0.000652	CcSEcCtD
Medrysone—NR3C1—AP-1 transcription factor network—CDKN1B—hematologic cancer	2.17e-05	0.00157	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—NR0B2—hematologic cancer	2.15e-05	0.00155	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—HES1—hematologic cancer	2.15e-05	0.00155	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—IL10—hematologic cancer	2.14e-05	0.00154	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—IL2—hematologic cancer	2.12e-05	0.00153	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—CASC3—hematologic cancer	2.12e-05	0.00153	CbGpPWpGaD
Medrysone—Hydrocortisone—NR3C1—hematologic cancer	2.12e-05	0.0173	CrCbGaD
Medrysone—Pain—Methotrexate—hematologic cancer	2.11e-05	0.000633	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—IFNG—hematologic cancer	2.1e-05	0.00152	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—hematologic cancer	2.09e-05	0.00151	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—CCND1—hematologic cancer	2.07e-05	0.00149	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—JUN—hematologic cancer	2.06e-05	0.00149	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—PTEN—hematologic cancer	1.99e-05	0.00144	CbGpPWpGaD
Medrysone—Pain—Epirubicin—hematologic cancer	1.97e-05	0.000592	CcSEcCtD
Medrysone—Progesterone—ESR1—hematologic cancer	1.96e-05	0.016	CrCbGaD
Medrysone—NR3C1—Generic Transcription Pathway—NCOR2—hematologic cancer	1.94e-05	0.0014	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—EP300—hematologic cancer	1.9e-05	0.00138	CbGpPWpGaD
Medrysone—Methylprednisolone—ABCB1—hematologic cancer	1.9e-05	0.0155	CrCbGaD
Medrysone—Testosterone—ABCG2—hematologic cancer	1.89e-05	0.0154	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—IL2—hematologic cancer	1.87e-05	0.00135	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—hematologic cancer	1.83e-05	0.00133	CbGpPWpGaD
Medrysone—Pain—Doxorubicin—hematologic cancer	1.82e-05	0.000548	CcSEcCtD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—JUN—hematologic cancer	1.82e-05	0.00131	CbGpPWpGaD
Medrysone—Hypersensitivity—Methotrexate—hematologic cancer	1.81e-05	0.000545	CcSEcCtD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—hematologic cancer	1.78e-05	0.00129	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—hematologic cancer	1.76e-05	0.00127	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—CREB1—hematologic cancer	1.75e-05	0.00126	CbGpPWpGaD
Medrysone—Progesterone—NR3C1—hematologic cancer	1.73e-05	0.0141	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—MAPK8—hematologic cancer	1.72e-05	0.00124	CbGpPWpGaD
Medrysone—Hypersensitivity—Epirubicin—hematologic cancer	1.7e-05	0.00051	CcSEcCtD
Medrysone—NR3C1—Adipogenesis—RB1—hematologic cancer	1.7e-05	0.00123	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—hematologic cancer	1.69e-05	0.00122	CbGpPWpGaD
Medrysone—NR3C1—Endoderm Differentiation—TGFB1—hematologic cancer	1.69e-05	0.00122	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—EP300—hematologic cancer	1.68e-05	0.00121	CbGpPWpGaD
Medrysone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—hematologic cancer	1.67e-05	0.0012	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—MYC—hematologic cancer	1.66e-05	0.0012	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—TGFB1—hematologic cancer	1.65e-05	0.0012	CbGpPWpGaD
Medrysone—Hypersensitivity—Doxorubicin—hematologic cancer	1.57e-05	0.000472	CcSEcCtD
Medrysone—NR3C1—SIDS Susceptibility Pathways—CREB1—hematologic cancer	1.51e-05	0.00109	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—hematologic cancer	1.5e-05	0.00109	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—hematologic cancer	1.47e-05	0.00107	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—IL6R—hematologic cancer	1.47e-05	0.00107	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	1.47e-05	0.00106	CbGpPWpGaD
Medrysone—Methyltestosterone—ALB—hematologic cancer	1.42e-05	0.0116	CrCbGaD
Medrysone—NR3C1—Gene Expression—RARS—hematologic cancer	1.37e-05	0.000987	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—TP53—hematologic cancer	1.36e-05	0.000984	CbGpPWpGaD
Medrysone—Prednisolone—ABCB1—hematologic cancer	1.34e-05	0.0109	CrCbGaD
Medrysone—NR3C1—Gene Expression—POLR3E—hematologic cancer	1.28e-05	0.000928	CbGpPWpGaD
Medrysone—NR3C1—AP-1 transcription factor network—IL6—hematologic cancer	1.25e-05	0.000901	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—PARP1—hematologic cancer	1.23e-05	0.000893	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—CDKN1A—hematologic cancer	1.22e-05	0.000881	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—TP53—hematologic cancer	1.2e-05	0.000867	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—IL1B—hematologic cancer	1.12e-05	0.00081	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—CASP3—hematologic cancer	1.12e-05	0.000808	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—RARA—hematologic cancer	1.11e-05	0.000805	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—TET2—hematologic cancer	1.11e-05	0.000805	CbGpPWpGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—IL6—hematologic cancer	1.1e-05	0.000794	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—RPLP1—hematologic cancer	1.09e-05	0.000789	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—STAT3—hematologic cancer	1.09e-05	0.000786	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—JUN—hematologic cancer	1.09e-05	0.000785	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NR0B2—hematologic cancer	1.03e-05	0.000748	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—AR—hematologic cancer	1.03e-05	0.000747	CbGpPWpGaD
Medrysone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—hematologic cancer	1.02e-05	0.000739	CbGpPWpGaD
Medrysone—Hydrocortisone—ABCB1—hematologic cancer	1.02e-05	0.00834	CrCbGaD
Medrysone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—hematologic cancer	1.01e-05	0.000732	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—TGFB1—hematologic cancer	1.01e-05	0.000729	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—EP300—hematologic cancer	1e-05	0.000724	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—DNMT3A—hematologic cancer	9.87e-06	0.000714	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—ELL—hematologic cancer	9.73e-06	0.000703	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—CDKN2B—hematologic cancer	9.51e-06	0.000688	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	9.49e-06	0.000686	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—TNF—hematologic cancer	9.41e-06	0.00068	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NCOR2—hematologic cancer	9.34e-06	0.000675	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—NCOR1—hematologic cancer	9.02e-06	0.000653	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—AGO2—hematologic cancer	8.61e-06	0.000623	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—DNMT3B—hematologic cancer	8.43e-06	0.00061	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—H3F3B—hematologic cancer	8.43e-06	0.00061	CbGpPWpGaD
Medrysone—Progesterone—ABCB1—hematologic cancer	8.33e-06	0.00679	CrCbGaD
Medrysone—Testosterone—ALB—hematologic cancer	8.25e-06	0.00673	CrCbGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—TNF—hematologic cancer	8.13e-06	0.000588	CbGpPWpGaD
Medrysone—Testosterone—ABCB1—hematologic cancer	7.87e-06	0.00642	CrCbGaD
Medrysone—NR3C1—Gene Expression—RPS14—hematologic cancer	7.71e-06	0.000558	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NUP98—hematologic cancer	7.59e-06	0.000549	CbGpPWpGaD
Medrysone—NR3C1—Adipogenesis—IL6—hematologic cancer	7.59e-06	0.000549	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NUP214—hematologic cancer	7.32e-06	0.000529	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—ESR1—hematologic cancer	7.09e-06	0.000513	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—NOTCH1—hematologic cancer	6.85e-06	0.000496	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—EIF4EBP1—hematologic cancer	6.74e-06	0.000488	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—HSPB1—hematologic cancer	6.74e-06	0.000488	CbGpPWpGaD
Medrysone—NR3C1—SIDS Susceptibility Pathways—IL6—hematologic cancer	6.56e-06	0.000474	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—SMC1A—hematologic cancer	6.46e-06	0.000467	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—H3F3A—hematologic cancer	6.33e-06	0.000458	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—CREBBP—hematologic cancer	6.21e-06	0.000449	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—EZH2—hematologic cancer	6.07e-06	0.000439	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—PARP1—hematologic cancer	5.94e-06	0.00043	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—HDAC2—hematologic cancer	5.73e-06	0.000415	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—AR—hematologic cancer	4.97e-06	0.000359	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—CDKN2B—hematologic cancer	4.58e-06	0.000331	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NCOR1—hematologic cancer	4.34e-06	0.000314	CbGpPWpGaD
Medrysone—NR3C1—Generic Transcription Pathway—MYC—hematologic cancer	3.69e-06	0.000267	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—MAPK14—hematologic cancer	3.48e-06	0.000252	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—ESR1—hematologic cancer	3.41e-06	0.000247	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—NOTCH1—hematologic cancer	3.3e-06	0.000239	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—CREBBP—hematologic cancer	2.99e-06	0.000216	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—MAPK3—hematologic cancer	1.83e-06	0.000132	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—MYC—hematologic cancer	1.78e-06	0.000128	CbGpPWpGaD
Medrysone—NR3C1—Gene Expression—AKT1—hematologic cancer	1.23e-06	8.9e-05	CbGpPWpGaD
